Drug profile · INN
erenumab
AIMOVIG
erenumab (AIMOVIG) is a calcitonin gene-related peptide type 1 receptor antagonist.
EMA: approved Nervous system (N02) N02CD01
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — erenumab
- Class
- Nervous system (N02)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
erenumab (AIMOVIG) is a calcitonin gene-related peptide type 1 receptor antagonist.
Key facts
INN erenumab
Brand AIMOVIG
Mechanism Calcitonin gene-related peptide type 1 receptor antagonist
Target Calcitonin gene-related peptide type 1 receptor
Therapeutic class Nervous system (N02)
ATC code N02CD01
Mechanism of action
Calcitonin gene-related peptide type 1 receptor antagonist
Primary target: Calcitonin gene-related peptide type 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is erenumab?
erenumab (AIMOVIG) is a calcitonin gene-related peptide type 1 receptor antagonist.
What is the brand name for erenumab?
AIMOVIG is a marketed brand name for erenumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.